TARRYTOWN, N.Y., Feb. 23, 2011 /PRNewswire/ — Regeneron
Pharmaceuticals, Inc. (Nasdaq:
REGN) will webcast management presentations at the following
Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on
Tuesday, March 1, 2011
RBC Capital Markets’ 2011 Healthcare Conference at 10:00 a.m.
Eastern Time on Wednesday, March 2, 2011
Cowen and Company 31st Annual Healthcare Conference at 1:20 p.m.
Eastern Time on Tuesday, March 8, 2011
Barclays Capital 2011 Global Healthcare Conference at 9:00 a.m.
Eastern Time on Wednesday, March 16, 2011
The sessions may be accessed through the Company’s web
site, www.regeneron.com, on the
Investor Relations page. Archived versions of the
presentations will be available for thirty days after the live
Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment
of serious medical conditions. In addition to ARCALYST®
(rilonacept) Injection for Subcutaneous Use, its first
commercialized product, Regeneron has therapeutic candidates in
Phase 3 clinical trials for the potential treatment of gout,
diseases of the eye (wet age-related macular degeneration and
central retinal vein occlusion), and certain cancers.
Additional therapeutic candidates developed from proprietary
Regeneron technologies for creating fully human monoclonal
antibodies are in earlier stage development programs in rheumatoid
arthritis and other inflammatory conditions, pain, cholesterol
reduction, allergic and immune conditions and cancer.
Additional information about Regeneron and recent news
releases are available on Regeneron’s web site at www.regeneron.com.Contact
Information:Michael Aberman, M.